HCA Healthcare lowers 2026 net income outlook to $6.3 bln-$6.7 bln from $6.495 bln-$7.035 bln
Company now sees 2026 revenues of $77 bln-$79.5 bln, versus prior $76.5 bln-$80 bln range
HCA expects 2026 adjusted EBITDA of $15.4 bln-$16.1 bln, down from $15.55 bln-$16.45 bln prior
Overview
US hospital operator's Q2 revenue rose 8.7% yr/yr; adjusted EPS up 11%
Company saw negative impact from payer mix shift, partly offset by Medicaid program benefits
HCA repurchased 4.75 mln shares for $2.06 bln in Q2
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 EPS
$7.62
Q2 Net Income
$1.93 bln
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 11 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the healthcare facilities & services peer group is "buy"
Wall Street's median 12-month price target for HCA Healthcare Inc is $462.50, about 22.8% above its July 23 closing price of $376.50
The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 15 three months ago
HCA•
